Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Alec Kimmelman
New York University School of Medicine, Department: Radiation Diagnostic/oncology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Vescor Therapeutics LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Vescor Therapeutics aims to develop novel therapeutics for cancer based on research in autophagy and the metabolism of cancer cells. The company's goal is related to the grant's goal of establishing how autophagy and the inhibition thereof affects the sensitivity of tumors to radiation therapy.
Investigating the Role of Autophagy in Pancreatic Cancer Radiation Resistance
Project Narrative: This proposal seeks to build on data from my laboratory showing that autophagy inhibition can sensitize pancreatic cancers to radiotherapy. Pancreatic cancer is highly lethal and current treatments such as chemotherapy and radiation are only minimally effective due to its profound therapeutic resistance. The results of these studies may have an important impact on the treatment of this disease.
Filed on October 10, 2017.
Tell us what you know about Alec Kimmelman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Alec Kimmelman filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Alec Kimmelman | New York University School of Medicine | Conflict of Interest | Vescor Therapeutics | $20,000 - $39,999 |
| Alec Kimmelman | New York University School of Medicine | Conflict of Interest | Vescor Therapeutics | Value cannot be readily determined |
| Alec Kimmelman | New York University School of Medicine | Conflict of Interest | Vescor Therapeutics LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.